Anti-ageing supplement stack evidence-based assessment showing what works and what doesn't

Is Your Anti-Ageing Stack Actually Working? 2026 Check

ByRohan Smith
Is Your Anti-Ageing Stack Actually Working? The 2026 Reality Check

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer

Most anti-ageing supplement stacks may lack meaningful outcome evidence. According to large-scale meta-analyses and randomised controlled trials (RCTs), the interventions most consistently associated with extended healthspan are resistance training, sleep regularity, and cardiometabolic risk optimisation — not off-label geroprotective drugs or NAD+ precursors. Many popular longevity protocols remain experimental for healthspan outcomes in the general population. [1-6]

2026 reality check: the best-supported longevity tools are still “boring but powerful” (exercise, sleep regularity, cardiometabolic risk optimisation). Many “anti-ageing stacks” and off-label drugs remain experimental for healthspan outcomes in the general population and may carry meaningful risks without appropriate monitoring. [2,5,6,13-18]

At a Glance

  • Resistance training and aerobic exercise are the most consistently supported longevity interventions, reducing cardiovascular mortality and preserving functional independence. [1,21]
  • Sleep duration of approximately 7-8 hours is associated with the lowest all-cause mortality risk in meta-analyses by Cappuccio et al. and Caputo et al. [3,4]
  • The PREDIMED trial demonstrated that a Mediterranean dietary pattern may reduce cardiovascular events by approximately 30% in higher-risk adults. [2]
  • Off-label rapamycin (mTOR inhibition) and metformin for non-diabetic longevity lack definitive healthspan outcome data in the general population. [14-18]
  • Omega-3 fatty acid supplementation shows potential cardiovascular benefit but carries an atrial fibrillation risk signal, particularly at doses above 1 g/day EPA+DHA. [9-11]
  • Creatine monohydrate has meta-analytic support for improving strength outcomes in older adults when combined with resistance training. [21]

Evidence Hierarchy for Longevity Interventions

Longevity research frequently conflates biomarker changes with hard clinical outcomes such as fewer cardiovascular events, fractures, or deaths. The distinction between surrogate endpoints and outcome data, as emphasised by the National Institutes of Health (NIH) and the Cochrane Collaboration, is critical for evaluating any anti-ageing protocol.

Evidence Tier Interventions Key Evidence
Most supported (low risk, high upside) Resistance training + aerobic activity, sleep regularity, smoking cessation Reliably improve risk factors and functional capacity linked to long-term outcomes [1-4]
Supported in the right context Mediterranean-style dietary patterns, evidence-based BP and lipid management PREDIMED RCT; Cholesterol Treatment Trialists’ Collaboration meta-analyses [2,5,6,12,13]
Mixed evidence / context-dependent risk Omega-3 supplementation (EPA/DHA) Potential CV benefit (Khan et al. 2021 meta-analysis) but atrial fibrillation risk signal (Gencer et al. 2021), especially at higher doses [9-11]
Insufficient evidence or higher risk Off-label rapamycin/rapalogs, metformin in non-diabetic individuals, many NAD+ booster regimens Biomarker shifts documented but long-term healthspan outcomes not established [13-20]

This differs from influencer-style protocols: an evidence-based longevity plan prioritises interventions with (a) outcome data or strong validated risk-proxy impact and (b) acceptable safety for your medical history and medication list. [2,5,6,9-12]

A Systems Audit for Longevity

Functional medicine approaches longevity as a systems audit, identifying the highest-leverage physiological constraints and addressing them with interventions matched to your individual risk profile, as recommended by the Australasian Society of Lifestyle Medicine (ASLM).

The “Big 5” Longevity Metrics

Metric What to Track Why It Matters
Blood pressure trend Home averages (morning and evening readings) SPRINT trial: intensive BP lowering reduced major cardiovascular events and mortality in higher-risk adults, though adverse events may increase — targets should be individualised [5,6]
Glycaemic regulation Fasting glucose, HbA1c, fasting insulin Insulin resistance is strongly linked to cardiovascular and cognitive outcomes via the HOMA-IR model
Lipid pattern ApoB, non-HDL cholesterol, LDL-C, triglycerides Provides a clearer “atherogenic burden” picture than total cholesterol alone [12,13]
Body composition and strength Lean mass, grip strength, functional capacity Muscle preserves metabolic resilience and reduces frailty risk; sarcopenia is a recognised geriatric syndrome [1,21]
Sleep duration and regularity Total sleep time, sleep-wake consistency, subjective quality Both short and long sleep duration are associated with higher all-cause mortality in the Cappuccio et al. and Caputo et al. meta-analyses [3,4]

Food Pattern That Best Matches Outcomes

The PREDIMED trial (Estruch et al., New England Journal of Medicine, 2013) demonstrated that a Mediterranean dietary pattern may reduce cardiovascular events in higher-risk groups. [2] In practice, it is less about a label and more about repeatable principles: high-fibre plants, legumes, nuts, extra-virgin olive oil, adequate protein (approximately 1.2-1.6 g/kg/day for older adults), and minimal ultra-processed foods.

Calorie Restriction: Promising, But Not Universally “Safe”

The CALERIE trial (Ravussin et al. 2015; Kraus et al. 2019) demonstrated that two-year human calorie restriction may improve several cardiometabolic risk markers, including fasting insulin, C-reactive protein (CRP), and blood pressure. [7,8] However, aggressive restriction can be problematic for some people (e.g., worsening sleep architecture, reduced lean mass, or triggering disordered eating patterns). A safer “longevity version” for many is: mild energy deficit (if needed) + adequate protein + progressive resistance training. [7,8,21]

Supplements: Signal vs. Caution

Supplement Evidence Summary Key Consideration
Creatine monohydrate Meta-analytic evidence (Sharifian et al. 2025) suggests improved strength-related outcomes when combined with resistance training in older adults Generally well tolerated; 3-5 g/day is the standard research dose [21]
Omega-3 (EPA/DHA) Khan et al. 2021 and Bernasconi et al. 2021 meta-analyses suggest potential cardiovascular outcome benefits Gencer et al. 2021 identified increased atrial fibrillation risk, particularly at doses above 1 g/day; risk/benefit should be individualised [9-11]
Vitamin D Ruiz-Garcia et al. 2023 meta-analysis (Nutrients) shows mixed results overall Benefits are most plausible in documented deficiency; routine high-dose vitamin D for “longevity” is not consistently supported [12]
Resveratrol and polyphenol extracts Mohammadipoor et al. 2022 meta-analysis shows improvements in some surrogate vascular markers Improved flow-mediated dilation is not the same as proven longevity benefit [22]
NMN/NAD+ boosters Yi et al. 2023 RCT shows NAD+ biomarkers can rise with acceptable short-term tolerability Long-term healthspan outcomes remain unclear; no outcome-level RCTs completed [19]

“Longevity Drugs”: Plausible Biology, Incomplete Outcomes

mTOR inhibitors (rapamycin/rapalogs): The mechanistic target of rapamycin (mTOR) pathway is strongly linked to cellular ageing biology in animal models. Human studies by Mannick et al. (2014, 2021) explored immune-related endpoints with some promising signals, including improved influenza vaccine response in older adults. [14,15] However, a comprehensive review by Roark et al. (2025) emphasises that using rapamycin off-label for “longevity” is not the same as treating an approved indication; safety is highly individual and the general-population healthspan case is not settled. [18]

Metformin: Metformin is established for type 2 diabetes management and has geroscience rationale via AMP-activated protein kinase (AMPK) activation. The TAME (Targeting Aging with Metformin) trial, proposed by Barzilai et al. (2016), aims to test whether metformin meaningfully extends healthspan in non-diabetic older adults, but results are not yet available. A critical review by Mohammed et al. (2021) concluded that the evidence for lifespan extension in non-diabetic humans remains debated. [16,17]

When to Consider (and When to Avoid) Longevity Interventions

Structured longevity planning may be most valuable when modifiable cardiometabolic risk factors are trending in the wrong direction, according to guidelines from the Royal Australian College of General Practitioners (RACGP) and the Heart Foundation of Australia.

You may want a structured longevity plan if you:

  • Have a strong family history of cardiometabolic disease or dementia
  • Notice declining strength, balance, or recovery capacity
  • Have persistent fatigue, sleep disruption, or unexplained waist circumference or weight changes
  • Have rising blood pressure, HbA1c/glucose, triglycerides, or inflammatory markers (e.g., hs-CRP) over time

You should be more cautious (and seek clinician oversight) if you:

  • Are pregnant or breastfeeding, have kidney or liver disease, or take anticoagulants or antiarrhythmics
  • Have a history of eating disorders (calorie restriction and aggressive tracking may be harmful)
  • Are considering off-label prescription drugs for “anti-ageing” outside a research setting [16-18]

If your longevity focus overlaps with persistent low energy, consider our perspective on fatigue and healthy ageing.

Next Steps

  1. Start with measurements, not stacks: home BP averages, waist circumference, weekly resistance training sessions, and sleep timing. [1,3,5]
  2. Pick the highest-leverage habit pair: (a) strength training + protein adequacy, (b) sleep regularity + morning light exposure, or (c) Mediterranean pattern + ultra-processed reduction. [1-3,21]
  3. Medical optimisation often outperforms supplement complexity: if BP, glucose, or lipids are trending the wrong way, discuss evidence-based options with your practitioner. [5,6,12,13]
  4. Use supplements as “gap fillers” only: consider creatine for strength support; omega-3 only with a clear rationale and dose safety; vitamin D based on measured serum 25(OH)D status. [9-12,21]
  5. Run single-variable experiments: change one input for 8-12 weeks, then reassess symptoms plus objective markers.

If you want a longevity plan that accounts for gut-driven inflammation and metabolic resilience, see gut microbiome and inflammation. If thyroid patterning is relevant to your energy, temperature tolerance, lipids, or weight trajectory, explore thyroid patterns and metabolic health. If stress/sleep rhythm appears central, clinician-guided testing may be discussed, including DUTCH Complete hormone testing or an Organic Acids Test (OAT).

Frequently Asked Questions

Is there one supplement that “slows ageing”?
No single supplement reliably slows ageing in humans. Some supplements can improve risk factors or performance in certain contexts, but outcomes depend on baseline status, medication interactions, and whether foundations (strength, sleep, cardiometabolic risk) are addressed first. [9-12,21,22]

Is fasting the best longevity tool?
Fasting can help some people reduce energy intake, but it can also worsen sleep, stress load, or lean mass if protein and strength training are not prioritised. Moderate, sustainable strategies with measurable cardiometabolic improvement are generally better supported than extreme patterns. The CALERIE trial data suggests moderate calorie restriction may be more sustainable than intermittent fasting for most individuals. [7,8]

Are rapamycin or metformin “safe” for longevity?
They have legitimate medical contexts and active research programs (including Mannick et al. for rapamycin and the TAME trial for metformin), but using them solely for longevity is not equivalent to treating a diagnosed condition. Evidence for broad healthspan extension in the general population is not definitive, and safety depends on dose, monitoring, and your medical history. The Therapeutic Goods Administration (TGA) in Australia has not approved either drug for anti-ageing indications. [14-18]

What is the most reliable longevity “fast win”?
For many people: improving blood pressure control (per the SPRINT trial findings), building strength through progressive resistance training, and stabilising sleep timing — because these shift multiple downstream risk pathways simultaneously. [1,3,5,6]

Key Insights

  • Longevity is mostly risk management: the best-supported strategies reduce cardiometabolic risk and preserve function [2,5,6,12,13]
  • Strength is a healthspan biomarker you can train: muscle is metabolic reserve and independence insurance [1,21]
  • Supplements are secondary: a few can support training or correct deficiency, while others show mixed outcomes and sometimes meaningful risks [9-12,19,21,22]
  • Off-label “anti-ageing drugs” remain research territory: plausible mechanisms are not the same as proven population-level benefits [16-18]

Citable Takeaways

  1. Leisure-time physical activity is associated with reduced all-cause mortality in a dose-response relationship, with the greatest benefit observed at 3-5 times the minimum recommended levels (Arem et al., JAMA Internal Medicine, 2015). [1]
  2. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts may reduce major cardiovascular events by approximately 30% compared to a reduced-fat control diet in high-risk adults (Estruch et al., NEJM, 2013). [2]
  3. Both short sleep duration (less than 6 hours) and long sleep duration (more than 9 hours) are associated with increased all-cause mortality risk, with approximately 7-8 hours showing the lowest risk in large meta-analyses (Cappuccio et al., 2010; Caputo et al., 2025). [3,4]
  4. The SPRINT trial found that intensive blood pressure control (targeting systolic BP below 120 mmHg) reduced cardiovascular events and all-cause mortality in adults at high cardiovascular risk, though with increased rates of some adverse events (Wright et al., NEJM, 2015). [5]
  5. Meta-analytic evidence suggests omega-3 supplementation may reduce cardiovascular events, but a dose-dependent increase in atrial fibrillation risk has been identified, particularly at doses exceeding 1 g/day EPA+DHA (Khan et al. 2021; Gencer et al. 2021). [9-11]
  6. Creatine monohydrate combined with resistance training may improve lean mass and strength outcomes in older adults, based on systematic review and meta-analysis of randomised controlled trials (Sharifian et al., 2025). [21]
  7. Mannick et al. (2014) demonstrated that mTOR inhibition with everolimus improved immune function in older adults, but off-label rapamycin use for longevity remains without definitive healthspan outcome data (Roark et al., 2025). [14,15,18]

Build a Longevity Plan That Actually Works

If you are in Adelaide and want an evidence-based longevity plan that prioritises safety, measurable outcomes, and your unique history, book a consultation with Elemental Health and Nutrition. We focus on what the evidence supports — not supplement hype — and tailor every recommendation to your specific risk profile and goals.

Book an Appointment

References

  1. Arem H, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015. https://pubmed.ncbi.nlm.nih.gov/25844730/
  2. Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet (PREDIMED). N Engl J Med. 2013. https://pubmed.ncbi.nlm.nih.gov/23432189/
  3. Cappuccio FP, et al. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010. https://pubmed.ncbi.nlm.nih.gov/20469800/
  4. Caputo M, et al. Sleep duration and all-cause mortality: dose-response meta-analysis. 2025. https://pubmed.ncbi.nlm.nih.gov/40047115/
  5. SPRINT Research Group; Wright JT Jr, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015. https://pubmed.ncbi.nlm.nih.gov/26551272/
  6. Williamson JD, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years or older. JAMA. 2016. https://pubmed.ncbi.nlm.nih.gov/27195814/
  7. Ravussin E, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction. J Gerontol A Biol Sci Med Sci. 2015. https://pubmed.ncbi.nlm.nih.gov/26187233/
  8. Kraus WE, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE). 2019. https://pubmed.ncbi.nlm.nih.gov/31303390/
  9. Khan SU, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. 2021. https://pubmed.ncbi.nlm.nih.gov/34505026/
  10. Bernasconi AA, et al. Effect of Omega-3 dosage on cardiovascular outcomes: a dose-response meta-analysis. 2021. https://pubmed.ncbi.nlm.nih.gov/32951855/
  11. Gencer B, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials. 2021. https://pubmed.ncbi.nlm.nih.gov/34612056/
  12. Ruiz-Garcia A, et al. Vitamin D supplementation and its impact on mortality and cardiovascular outcomes: systematic review and meta-analysis. Nutrients. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10146299/
  13. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people. Lancet. 2019. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext
  14. Nanna MG, et al. Primary Prevention Statin Therapy in Older Adults. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9830552/
  15. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/
  16. Mannick JB, et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults. 2021. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00062-3/fulltext
  17. Mohammed I, et al. A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8374068/
  18. Barzilai N, et al. Metformin as a Tool to Target Aging. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/
  19. Roark KM, et al. Rapamycin for longevity: the pros, the cons, and future perspectives. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/
  20. Yi L, et al. The efficacy and safety of NMN supplementation in healthy middle-aged adults: a randomized clinical trial. 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
  21. Sharifian G, et al. Impact of creatine supplementation and exercise training in older adults: a systematic review and meta-analysis. 2025. https://pubmed.ncbi.nlm.nih.gov/41062952/
  22. Mohammadipoor N, et al. Resveratrol supplementation and endothelial health: systematic review and meta-analysis of randomized controlled trials. 2022. https://pubmed.ncbi.nlm.nih.gov/35833325/

Ready to find answers?

Stop surviving. Start recovering.

Similar Posts